SciELO - Scientific Electronic Library Online

 
vol.24 número3Uso del factor VII activado recombinante en pacientes no hemofílicos en CubaInfiltración extramedular en la leucemia mielomonocítica crónica (LMMC) índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Hematología, Inmunología y Hemoterapia

versión impresa ISSN 0864-0289versión On-line ISSN 1561-2996

Resumen

AGRAMONTE LLANES, Olga M et al. Use of recombinat activated factor VII in Rendú-Osler-Weber's disease or hereditary hemorrhagic talangiectasia and digestive bleeding: First case reported in Cuba. Rev Cubana Hematol Inmunol Hemoter [online]. 2008, vol.24, n.3. ISSN 0864-0289.

The recombinat activated factor VII (rFVIIa Novoseven, Novonordisk, Denmark) has been successfully used in the treatment of hemorrhages in hemophilic patients with inhibitors, in the congenital deficiency of FVII and in Glanzmann's thromboasthenia. Besides, its use has been recommended in non-hemoplilic patients with acquired antibodies against FVIII (acquired hemophilia) and in other disorders of the platelet function as Bernard Soulier Syndrome (SBS). When it is administered at pharmacological doses, it increases the generation of thrombin on the activated platelet, and it may be benefitial in other disorders characterized by profuse bleeding and inadequate generation of thrombin, such as the thrombocytopenias. It has been used in hemorrhages secondary to alterations of the liver function and in severe trauma. Its administration to patients with Rendú Osler Weber's disease and severe bleedings is a new indication, taking into account the activation of coagulation in the specific site of the lesion. It is reported the favorable response of a patient with severe digestive bleeding endangering his life that received rFVII at doses of 90 µg/kg until completing 3 doses in 24 hours. The hemorrhage stopped and its potent hemostatic character in uncontrollable bleedings was confirmed

Palabras clave : rFVIIa; non-hemophilic patients; liver transplant; Rendú Osler Weber's disease.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons